Menstrual Products – Performance Testing and Labeling Recommendations
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies
Why this guidance matters In the evolving world of biologics and biosimilars, precise head-to-head clinical trials are expensive, lengthy and sometimes redundant. The FDA recognises this, and in this draft guidance it offers a refined framework to decide when a Comparative Efficacy Study (CES) is really needed — and when it may be safely omitted. […]
New FDA Draft Guidance: Elevating Safety, Transparency & Testing for Menstrual Products
Introduction In October 2025, the FDA published a draft guidance titled Menstrual Products – Performance Testing and Labeling Recommendations (Draft Guidance for Industry and FDA Staff). U.S. Food and Drug AdministrationThis guidance provides non-binding recommendations for manufacturers of menstrual products (tampons, pads, menstrual cups) regarding performance testing, specification, materials/disclosure, and labeling. U.S. Food and Drug […]
Unlocking the Future of Drug Development: How the FDA’s New Radiolabeled Mass-Balance Study Guidance Is Changing the Game
🧠 Article: The U.S. Food & Drug Administration (FDA) has released a pivotal guidance document — “Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies” — which outlines its current thinking on when and how to conduct human radiolabeled mass-balance studies of investigational drugs. U.S. Food and Drug Administration Here’s a breakdown of what this […]
Putting Patients in the Driver’s Seat: How the FDA’s Latest Guidance is Changing the Game for Clinical Trials
1. What’s this all about? The U.S. Food & Drug Administration (FDA) has released a new guidance titled “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments”. U.S. Food and Drug AdministrationHere’s the gist: 2. Why this matters In the past, many clinical trials were designed and measured mainly from a “clinician/regulator” perspective. […]
Title: Decoding the FDA’s New Data Submission Framework for Acute Leukemia Trials: A Step Toward Smarter, Faster, and Safer Approvals
Introduction: Setting a New Benchmark in Oncology Research The U.S. Food and Drug Administration (FDA) has taken a major stride in refining how clinical trial data for acute leukemia treatments are organized, analyzed, and submitted. With the release of the Technical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute […]
A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
Understanding the FDA’s Key Developments on Drug Approvals and Public Health: A Deep Dive into the Latest FDA Release
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in safeguarding public health by regulating food, drugs, medical devices, and more. The FDA’s guidance and regulations are not only pivotal in ensuring safety but also in shaping the future of medical innovations and treatments. Recently, the FDA released a comprehensive document outlining […]